Lamivudine/raltegravir

Lamivudine/raltegravir
Combination of
Lamivudine	Reverse-transcriptase inhibitor
Raltegravir	Integrase inhibitor
Clinical data
Trade names	Dutrebis
Routes of; administration	Oral
ATC code	J05AR16 (WHO) ;
Legal status
Legal status	US: ℞-only;
Identifiers
CAS Number	2446160-46-7;
KEGG	D10754;

Lamivudine/raltegravir, sold under the brand name Dutrebis, is a fixed-dose combination antiretroviral medication used in the treatment of HIV/AIDS.^[1] It contains lamivudine and raltegravir. It is taken by mouth.^[1] Side effects may include lactic acidosis, pancreatitis, liver failure, and severe skin rashes.^[1] It was approved for medical use in the United States in 2015.^[1]^[2]

Lamivudine/raltegravir is not available in the United States.^[3]

References

^ ^a ^b ^c ^d "Dutrebis (lamivudine and raltegravir)" (PDF). U.S. Food and Drug Administration (FDA). Retrieved 10 December 2017.
^ "Dutrebis (lamivudine and raltegravir) tablet". U.S. Food and Drug Administration (FDA). 11 April 2016. Retrieved 24 January 2020.
^ "Dutrebis (lamivudine and raltegravir) FDA Approval History". Drugs.com. 6 February 2015. Retrieved 24 January 2020.

External links

"Lamivudine mixture with raltegravir". Drug Information Portal. U.S. National Library of Medicine.

This antiinfective drug article is a stub. You can help Wikipedia by expanding it.

Zdroj:https://en.wikipedia.org?pojem=Lamivudine/raltegravir
Text je dostupný za podmienok Creative Commons Attribution/Share-Alike License 3.0 Unported; prípadne za ďalších podmienok. Podrobnejšie informácie nájdete na stránke Podmienky použitia.

[FDA2015-1] "Dutrebis (lamivudine and raltegravir)" (PDF). U.S. Food and Drug Administration (FDA). Retrieved 10 December 2017.

[2] "Dutrebis (lamivudine and raltegravir) tablet". U.S. Food and Drug Administration (FDA). 11 April 2016. Retrieved 24 January 2020.

[3] "Dutrebis (lamivudine and raltegravir) FDA Approval History". Drugs.com. 6 February 2015. Retrieved 24 January 2020.

[1]

[2]

[3]